Total: $51.25M Year to Date: $598.94M | ||||
Company |
Partner |
Amt. |
Details |
Date |
Incyte Corp. (Wilmington, Del.) |
Eli Lilly and Co. (Indianapolis) |
$50 |
For the formal initiation of the rheumatoid arthritis Phase III program for baricitinib, Incyte's oral JAK1/JAK2 inhibitor, formerly known as INCB28050 |
11/16/12 |
Isis Pharmaceuticals Inc. (Carlsbad, Calif.) |
Pfizer Inc. (New York) |
$1.25 |
For Pfizer's decision to advance the antiscarring therapy EXC 001 into a Phase II study |
11/5/12 |
Notes: Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. ND = Not disclosed. |